New triplet therapy aims to control resistant breast cancer
NCT ID NCT07405801
First seen Feb 17, 2026 · Last updated May 08, 2026 · Updated 16 times
Summary
This study tests whether adding the drug inavolisib to a standard two-drug combination (ribociclib and fulvestrant) can shrink tumors or slow disease progression in people with a specific type of advanced breast cancer (HR+/HER2- with chromosome 8p loss). About 80 participants whose cancer has stopped responding to hormone therapy will receive either the three-drug combo or a placebo plus the two standard drugs. The main goal is to see how many patients have a significant tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AMG Oncology and Hematology Avera Cancer Institute - Yankton
RECRUITINGYankton, South Dakota, 57078, United States
-
Avera Cancer Institute
RECRUITINGSioux Falls, South Dakota, 57105, United States
-
Avera Cancer Institute - Aberdeen
RECRUITINGAberdeen, South Dakota, 57401, United States
-
Avera Cancer Institute - Marshall
RECRUITINGMarshall, Minnesota, 56258, United States
-
Avera Cancer Institute - Mitchell
RECRUITINGMitchell, South Dakota, 57301, United States
-
Avera Cancer Institute - Pierre, SD
RECRUITINGPierre, South Dakota, 57501, United States
-
CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital
RECRUITINGChicoutimi, Quebec, G7H 5H6, Canada
-
Centro Oncologico Korben
RECRUITINGCaba, C1426AGE, Argentina
-
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
RECRUITINGSão Paulo, São Paulo, 01317-000, Brazil
-
Gachon University Gil Medical Center
RECRUITINGNamdong-Gu, 21565, South Korea
-
Hospital Brasilia
RECRUITINGBrasília, Federal District, 71.635-610, Brazil
-
Hospital Santa Rita de Cassia Vitoria
RECRUITINGVitória, Espírito Santo, 29043-260, Brazil
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Clínico San Cecilio
RECRUITINGGranada, 18016, Spain
-
ICTR Curitiba
RECRUITINGCuritiba, Paraná, 80510-130, Brazil
-
McGill University
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, 13605, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Soon Chun Hyang University Cheonan Hospital
RECRUITINGDongnam-gu, Cheonan-si, 31151, South Korea
Conditions
Explore the condition pages connected to this study.